Key result
MitraClip compared to medical therapy alone in patients with less severe functional mitral regurgitation reduces heart failure hospitalizations and improves symptoms.
Why the study?
Does MitraClip reduce hospitalizations for heart failure and improve symptoms in patients with symptomatic heart failure and less severe functional mitral regurgitation?
Does MitraClip reduce hospitalizations for heart failure and improve symptoms in patients with symptomatic heart failure and less severe functional mitral regurgitation?
MitraClip provides symptomatic and hospitalization benefits in patients with less severe functional mitral regurgitation, especially those at high risk for heart failure exacerbation.
), is associated with a significant reduction in hospitalizations for heart failure, and an improvement in symptoms and quality of life, without a clear benefit on mortality. However, within the cohort of patients with less severe MR enrolled in the RESHAPE-HF2 study, the benefits of MitraClip compared to medical therapy alone seem more significant in selected patients with characteristics associated with a higher risk of heart failure exacerbation, suggesting the importance of careful selection of patients with symptomatic heart failure and MR who could benefit from TEER.
No takes yet. Share an insight, caveat, or question.
Capranzano et al. (2025) conducted an editorial in Symptomatic heart failure and less severe functional mitral regurgitation. MitraClip (TEER) vs. Medical therapy alone was evaluated on Hospitalizations for heart failure, symptoms, quality of life, and mortality. MitraClip compared to medical therapy alone in patients with less severe functional mitral regurgitation reduces heart failure hospitalizations and improves symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: